Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
UBS
US Army
Chinese Patent Office
Express Scripts
Colorcon
Cipla
Citi
Julphar

Generated: February 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,320,714

« Back to Dashboard

Which drugs does patent 9,320,714 protect, and when does it expire?

Patent 9,320,714 protects ACTOPLUS MET and is included in one NDA.

This patent has six patent family members in six countries.
Summary for Patent: 9,320,714
Title:Tablet
Abstract: The present invention can retain the volume of a tablet large without increasing the thickness of the tablet or the like dimension and prevents a plurality of tablets from sticking to each other even if they are subjected to a film-coating or the like treatment, so as to improve the yield. The tablet is a tablet (1) longer in one direction when seen in plan. The tablet (1) has side edges (6) each of which extends in a longitudinal direction and is formed in the shape of a curve projecting outwardly in plan view. The curve has a radius of curvature (R1) set to at least 1.5 times a length (L) of the tablet. This makes a projected area of the tablet (1) in plan view at least 97% with respect to a projected area of a standard elliptical tablet having opposite end portions each of which is formed by a semi-circle having a diameter of a width (W) of the tablet.
Inventor(s): Koike; Masahiko (Osaka, JP), Koyama; Hiroyoshi (Osaka, JP)
Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED (Osaka-Shi, JP)
Application Number:13/082,890
Patent Claim Types:
see list of patent claims
Dosage form;

Drugs Protected by US Patent 9,320,714

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Takeda Pharms Usa ACTOPLUS MET metformin hydrochloride; pioglitazone hydrochloride TABLET;ORAL 021842-001 Aug 29, 2005 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Takeda Pharms Usa ACTOPLUS MET metformin hydrochloride; pioglitazone hydrochloride TABLET;ORAL 021842-002 Aug 29, 2005 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,320,714

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2005-102578Mar 31, 2005

International Patents Family Members for US Patent 9,320,714

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal 1867324 ➤ Try a Free Trial
Japan 5022893 ➤ Try a Free Trial
Japan WO2006106815 ➤ Try a Free Trial
European Patent Office 1867324 ➤ Try a Free Trial
Spain 2593469 ➤ Try a Free Trial
Canada 2602184 ➤ Try a Free Trial
World Intellectual Property Organization (WIPO) 2006106815 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Covington
Johnson and Johnson
Colorcon
AstraZeneca
Chubb
Moodys
McKinsey
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot